$VVOS

Vivos Therapeutics, Inc. reported its Q4 2025 earnings, exceeding analyst expectations with a significant increase in revenue. The company's focus on innovative treatments for sleep apnea and related disorders has attracted positive attention from investors. Despite the growth, some experts express caution due to ongoing competition in the healthcare sector. Management highlighted their plans for expansion and potential new product lines, which could drive future growth. Overall, the earnings report positions VVOS favorably in the market, though investors should remain vigilant about competitive pressures.